Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay
of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens …

Prostate cancer (PCa) incidence and mortality have rapidly increased in China. Notably,
unique epidemiological characteristics of PCa are found in the Chinese PCa population …

Tissue damage increases the risk of cancer through poorly understood mechanisms. In
mouse models of pancreatic cancer, pancreatitis associated with tissue injury collaborates …

Emerging evidence indicates that various cancers can gain resistance to targeted therapies
by acquiring lineage plasticity. Although various genomic and transcriptomic aberrations …

Tumor mutational burden and heterogeneity has been suggested to fuel resistance to many
targeted therapies. The cytosine deaminase APOBEC proteins have been implicated in the …

Despite the development of second-generation antiandrogens, acquired resistance to
hormone therapy remains a major challenge in treating advanced prostate cancer. We find …

Cancers adapt to increasingly potent targeted therapies by reprogramming their phenotype.
Here we investigated such a phenomenon in prostate cancer, in which tumours can escape …

Metastatic castration-resistant prostate cancer (PC) is the final stage of PC that acquires
resistance to androgen deprivation therapies (ADT). Despite progresses in understanding of …

The introduction of second-generation androgen receptor antagonists (SG-ARAs) has
greatly impacted the treatment of metastatic prostate cancer, providing tolerable and …

Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …